Related Experiment Video
Updated: Jun 24, 2026
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Optimizing recent advances in metastatic renal cell carcinoma
Kevin D Courtney1, Toni K Choueiri
1Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.
Current Oncology Reports
|April 2, 2009
Summary
Recent advances in metastatic renal cell carcinoma (RCC) treatment include targeted therapies like tyrosine kinase inhibitors and anti-angiogenesis agents. Future efforts focus on personalized treatment, novel combinations, and new therapeutic targets for improved outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Metastatic renal cell carcinoma (RCC) treatment has advanced significantly.
- Molecular pathway dissection has yielded targeted therapies.
Purpose of the Study:
- To review recent advances in metastatic RCC treatment.
- To outline future challenges and directions in therapy development.
Main Methods:
- Review of targeted therapies including receptor tyrosine kinase inhibitors (sunitinib, sorafenib), anti-VEGF antibody (bevacizumab), and rapamycin analogues (everolimus, temsirolimus).
- Discussion of clinical efficacy of these agents in metastatic RCC.
Main Results:
- Several targeted agents demonstrate clinical efficacy in metastatic RCC.
- Current therapies include sunitinib, sorafenib, bevacizumab, everolimus, and temsirolimus.
Conclusions:
- Future research should focus on patient selection for targeted therapies.
- Optimizing therapy combinations, sequences, and developing novel agents are crucial.
- Identifying new therapeutic targets is essential for expanding RCC treatment options.
